The first “Alzheimer’s village” in France will welcome 120 patients, accompanied by a hundred caregivers and volunteers. Work begins on Monday, June 4, near Dax, in the Landes.
This Monday, June 4 begins the construction of the first Alzheimer village of France, which will soon emerge from the ground in Dax, in the Landes. This new structure will accommodate 120 patients, accompanied by around 100 caregivers and volunteers.
Maintain residents’ participation in social life
The goal: to measure the impact of these new methods of less drug-based treatment on the patient’s quality of life. the Alzheimer village aims “to maintain the participation of residents in social life”, explains daily The world Jean-François Dartigues, neurologist and epidemiologist at CHU Pellegrin in Bordeaux. This structure “integrates a research center which will carry out a comparative study with traditional establishments, of the impact of new therapeutic approaches on patients, caregivers and caregivers”, specifies the professor.
While this pathology of aging is incurable today, it has been established that social interactions slow the progression of the disease, in particular through the stimulation of intellectual activities.
Intellectual activities
To reach these conclusions, researchers have studied a cohort of 15,582 Chinese aged 65 or over living in community. None suffered from dementia. The follow-up lasted five years. A total of 1,349 people (8.7%) developed dementia.
A very encouraging figure, when we know that Alzheimer’s disease alone affects nearly 10% of people over 65 in France. The intellectual activities performed by the cohort were as simple as reading books, newspapers or magazines, playing board or card games, and betting on horse races.
100,000 to 150,000 new cases
Alzheimer’s disease was put in the spotlight last week, with Minister of Health Agnès Buzyn announcing controversial delisting certain drugs by social security. “I confirm the delisting of anti-Alzheimer drugs, and it is absolutely not for budgetary reasons. It is because these drugs have been shown by the HAS as being harmful and causing a lot of side effects, with fractures and falls. We de-reimburse so that people no longer use them “, she explained, Wednesday, May 30, on the set of” 19/20 “of France 3.
Alzheimer’s and related dementias affect around one million patients in France. 100,000 to 150,000 new cases are reported each year.
.